new delhi it was noncompliance with good manufacturing practices gmp at bharat biotechs flagship vaccine manufacturing facility at hyderabads genome valley that led to the world health organisation who suspending covaxin supply for un procurementconfirming this who told toi that the inspection it had carried out between march 14 and 22 found that the manufacturing site for the production of the covid vaccine covaxin located in telangana india is not compliant with gmp and systemic issues need to be addressed problems were detected in some parts of the manufacturing process and changes were made after the eul emergency use listing was granted but were not submitted to the national drug regulator and who for evaluation the inspection was part of an campaign of manufacturing sites in india who said